As an adjunctive treatment, empagliflozin improves glycaemic control in patients with HNF1A-related maturity-onset diabetes ...

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

Abbott Laboratories (NYSE:ABT) detailed fourth-quarter 2025 results and outlined its 2026 outlook on its earnings conference call, emphasizing continued momentum in medical devices, a transition plan ...

Objectives: Electronic health record (EHR) systems are central to modern practice yet contribute to physician workload and burnout. Metrics such as documentation timeliness, efficiency, and ...